文献速递湿疹皮炎与荨麻疹

度普利尤单抗对中重度特应性皮炎幼儿照护者与患者报告结局的影响:一项安慰剂对照3期研究结果

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study.
PubMed 文献 · J Am Acad Dermatol · 2024-09-28

LIBERTY AD PRESCHOOL随机安慰剂对照研究的事后分析评估度普利尤单抗对6个月至5岁中重度特应性皮炎患儿照护者报告症状及患者与家庭生活质量的影响。度普利尤单抗组83例、安慰剂组79例,治疗16周;度普利尤单抗较安慰剂显著改善照护者报告的AD症状与生活质量,第4周即见显著改善并持续至研究结束,同时快速显著改善照护者/家庭的生活质量指标。

要点

  • 度普利尤单抗显著改善幼儿中重度AD的照护者报告症状与生活质量。
  • 改善最早在第4周出现并持续至16周研究结束。
  • 度普利尤单抗快速显著改善患儿照护者/家庭的生活质量。

核心结论

  • 度普利尤单抗改善中重度AD幼儿的AD症状及患者和照护者/家庭的生活质量。

研究设计与样本

  • LIBERTY AD PRESCHOOL随机安慰剂对照研究的事后分析,纳入6个月至5岁中重度AD患儿,接受度普利尤单抗或安慰剂联合低效价外用糖皮质激素治疗16周。
  • 度普利尤单抗组n=83,安慰剂组n=79。

主要发现

  • 度普利尤单抗较安慰剂在照护者报告的AD症状(如瘙痒和睡眠)及生活质量方面提供显著改善。
  • 显著改善最早在第4周出现并持续至研究结束。
  • 度普利尤单抗较安慰剂快速且显著改善患者照护者/家庭的生活质量指标。

关键数值与推荐

  • 主要评估指标为基线至第16周照护者报告结局指标(AD症状如瘙痒和睡眠)及患者与照护者/家庭生活质量的变化。

临床怎么用

  • 对于6个月至5岁中重度AD幼儿,度普利尤单抗联合低效价外用糖皮质激素可改善照护者报告的症状及患者与家庭生活质量。

局限性

  • 年龄<2岁的患者较少。
  • 仅对预设终点报告显著性。
  • 婴儿皮炎生活质量指数严重度分层采用儿童皮肤病生活质量指数的分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) greatly impacts children/caregivers. OBJECTIVE: Evaluate the impact of treatment with dupilumab on caregiver- and patient-reported AD symptoms and quality of life (QoL) in young children. METHODS: In the LIBERTY AD PRESCHOOL (randomized, placebo-controlled) study, children aged 6 months to 5 years with moderate-to-severe AD received dupilumab or placebo plus low-potency topical corticosteroids for 16 weeks. This posthoc analysis assessed the change from baseline to week 16 in caregiver-reported outcome measures of AD symptoms (eg, itch and sleep) and QoL of patients and their caregivers/families. RESULTS: Dupilumab (n = 83) vs placebo (n = 79) provided significant improvements in caregiver-reported AD symptoms and QoL. Significant improvements were seen as early as week 4 and sustained through the end of the study. Additionally, dupilumab vs placebo provided rapid and significant improvement in QoL measures for the patients' caregivers/families. LIMITATIONS: Few patients aged <2 years; significance only reported for prespecified endpoints; Infant's Dermatitis QoL Index severity strata adopted from Children's Dermatology Life Quality Index. CONCLUSION: Dupilumab improved AD symptoms and QoL in patients and their caregivers/families.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Silverberg JI, Simpson EL, et al. The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study. J Am Acad Dermatol. 2024. PMID: 39349183. doi:10.1016/j.jaad.2024.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。